Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases

Abstract

The preset invention relates to combination pharmaceutical composition comprising an activated-potentiated from of an antibody to gamma interferon, and an activated-potentiated form of an antibody to S-100 protein and method of treating multiple sclerosis and other neurodegenerative diseases, as well as the diseases and conditions associated with neuroinfections.

1 - 36 . (canceled) 
     
     
         37 . A method of reducing the frequency of appearance of relapse in a patient suffering from multiple sclerosis by administrating to a patient in need thereof a therapeutically effective amount of an activated-potentiated form of an antibody to S-100 protein. 
     
     
         38 . The method of  claim 37 , wherein the activated-potentiated form of an antibody to S-100 protein is administered in one to two unit dosage forms, each dosage form being administered from once daily to four times daily. 
     
     
         39 . The method of  claims 37 , wherein the activated-potentiated form of an antibody to S-100 protein is administered in one to two unit dosage forms, each dosage form being administered twice daily. 
     
     
         40 . The method of  claim 37 , wherein the activated-potentiated form of an antibody is to the S-100 protein comprising the amino acid sequence of SEQ ID NO 14. 
     
     
         41 . The method of  claim 37  wherein the activated-potentiated form of an antibody is to the S-100 protein comprising the amino acid sequence of SEQ ID NO 17. 
     
     
         42 . The method of  claim 37 , wherein the activated-potentiated form of an antibody to S-100 protein is in the form of mixture of C12, C30, and C50 homeopathic dilutions subsequently impregnated onto the solid carrier. 
     
     
         43 . The method of  claim 37 , wherein the activated-potentiated form of an antibody to S-100 protein is in the form of mixture of C12, C30, and C200 homeopathic dilutions subsequently impregnated onto the solid carrier. 
     
     
         44 . The method of  claim 37 , wherein the activated-potentiated form of an antibody to S-100 protein is a monoclonal, polyclonal or natural antibody. 
     
     
         45 . The method of  claim 37 , wherein the activated-potentiated form of an antibody to S-100 protein is a polyclonal antibody. 
     
     
         46 . The method of  claim 37 , wherein the activated-potentiated form of an antibody to S-100 protein is prepared by successive centesimal dilutions coupled with shaking of every dilution.